| DID | Title | Description | URL |
| 1 | PROVIDE trial | A PERSONALIZED RANDOMIZED TRIAL OF VALIDATION AND RESTORATION OF IMMUNE DYSFUNCTION IN SEVERE INFECTIONS AND SEPSIS | https://sepsisonline.org/Default.aspx |
| 2 | SAVE-MORE trial | suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19:
THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL | https://savemore.sepsis.gr |
| 3 | IMMUNOSEP trial | PERSONALIZED IMMUNOTHERAPY IN SEPSIS: A MULTICENTRE AND MULTINATIONAL, DOUBLE-BLIND, DOUBLE-DUMMY RANDOMIZED CLINICAL TRIAL | https://sepsisonline.org |
| 4 | Η ΜΕΛΕΤΗ BEYOND | Η ΑΠΟΤΕΛΕΣΜΑΤΙΚΟΤΗΤΑ ΤΗΣ ΜΠΕΖΛΟΤΟΞΟΥΜΑΜΠΗΣ
ΣΤΙΣ ΕΞΑΤΟΜΙΚΕΥΜΕΝΕΣ ΑΝΑΓΚΕΣ ΑΣΘΕΝΩΝ ΜΕ ΛΟΙΜΩΞΗ
ΑΠΟ CLOSTRIDIOIDES DIFFICILE | https://beyond.sepsis.gr |
| 5 | ACCESS trial | A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia
to attenuatE inflammatory responseS and improve outcomeS | https://www.access-trial.org |
| 6 | INSPIRE trial | IMMUNOTHERAPY NAVIGATED BY SERUM
PRESEPSIN FOR INFECTIONS OF THE RESPIRATORY TRACT:
THE INSPIRE DOUBLE-BLIND, RANDOMIZED, PHASE IIa EXPLORATORY TRIAL | https://inspiretrial.org |
| 7 | MODIFY trial | A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS PROCALCITONIN-GUIDANCE AND
MOLECULAR-GUIDED DIAGNOSIS AS MAINSTAY FOR THERAPY OF SEVERE INFECTIONS | https://www.modifysepsis.org |
| 8 | PRECISION trial | Safety and efficacy of Anakinra treatment for patients with
Persistent REspiratory symptoms post acute COVID and Immune System activatION
The PRECISION double-blind, randomized clinical trial | https://www.precision-trial.org |
| 9 | BioArte trial | DEVELOPMENT OF A NON-INTERVENTIONAL DIAGNOSTIC NGS-BASED ASSAY OF BLOOD SAMPLES OF SEPSIS PATIENTS FOR RAPID BACTERIAL IDENTIFICATION BASED ON NEXT GENERATION SEQUENCING | https://bioarte.sepsis.gr |
| 10 | REACT trial | BIOMARKER-GUIDED EARLY CLARITHROMYCIN TREATMENT TO
PREVENT SEPSIS PROGRESSION IN COMMUNITY-ACQUIRED
PNEUMONIA: THE REACT RANDOMIZED CLINICAL TRIAL | https://reactcrf.org |